BBIO enters its August 10 earnings report with options traders firmly positioned for upside — a notable contrast to the elevated short interest that has built steadily over the past month.
The clearest signal heading into the print is in options, where call positioning has overwhelmed puts by a striking margin. The put/call ratio has collapsed to 0.19, near the 52-week low of 0.12 and well below its 20-day average of 0.24. That near-floor reading points to heavy call demand relative to hedging activity — options traders are leaning bullish into tonight's release. The stock reinforces this tone: up 8% over the past month and 5% on the week to close at $84.48, BBIO has been in a steady grind higher. That momentum softened briefly on July 31, the one session where the PCR spiked to its 52-week high of 1.17 — a one-day defensive flush that has since fully reversed.
Short interest tells a more complicated story. Bears have built a meaningful position, with roughly 13.5% of the free float sold short — a level that qualifies as genuinely elevated for a biotech of this stage. That figure has crept up about 4% over the past month, reaching approximately 26 million shares. Yet the borrow market is anything but stressed: availability is at 1,255% of short interest, meaning there are more than twelve shares available to borrow for every one already shorted. Borrowing costs remain low at 0.59% annualised, even after rising 27% on the week — a directional move that bears watching but still a far cry from a squeeze dynamic. The short score has drifted to 60, consistent with a stock that shorts have a view on but are not aggressively piling into at the margin.
The analyst community is broadly constructive but divided on conviction. The mean price target of $106 implies roughly 25% upside from current levels, with most recent moves in the bullish direction — HC Wainwright lifted its target to $120 in mid-July, and Citigroup raised its neutral-rated target from $82 to $93. Morgan Stanley maintained Overweight with a $98 target in late May. The lone dissent came from Raymond James, which downgraded to Market Perform without a target in late May. The bull case centres on Attruby's position in transthyretin amyloid cardiomyopathy — recently strengthened by a competitor's trial failure — plus the $900 million preferred financing that removes near-term capital pressure. Bears point to negative book value, deeply negative earnings multiples, and the risk that the stock's valuation has run ahead of pipeline execution. EPS surprise ranks in the 84th percentile historically, a record that suggests the company has consistently managed expectations well.
Institutional ownership adds one notable data point. Viking Global trimmed its position by roughly 2 million shares as of early July, while Farallon and BlackRock have been adding. Director Jennifer Cook sold over $13 million in stock across late June and early July — significant in dollar terms, though trade-significance scores remain low, consistent with pre-planned disposals rather than conviction selling.
The print will test whether Attruby's commercial ramp is tracking the trajectory that justifies a stock trading near the top of its range, and whether management's pipeline commentary confirms or complicates the bull thesis that has driven calls to near-record dominance over puts.
See the live data behind this article on ORTEX.
Open BBIO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
